A new clinical trial platform—designed to test multiple experimental treatments for pancreatic cancer therapies at the same time—has the potential to reduce the time it takes for people with cancer to enroll in a trial and speed up the approval of new treatments. Launched by the Pancreatic Cancer Action Network (PanCAN), the platform, called Precision Promise℠, has 15 sites across the United States, including NYU Langone Health’s Perlmutter Cancer Center. Diane M. Simeone, MD, the Laura and Isaac Perlmutter Professor of Surgery in the Department of Surgery and director of Perlmutter Cancer Center’s Pancreatic Cancer Center, is the national principal investigator for Precision Promise℠ at Perlmutter Cancer Center.
“Pancreatic cancer is a difficult enough diagnosis to navigate in and of itself,” Dr. Simeone tells SurvivorNet. “So to have a national program like this with centers around the country that have specific expertise in pancreatic cancer, to make it easier for patients to know what options they have and give them more promising new therapies in a way that hasn’t happened before, it’s very exciting.”
Read more from SurvivorNet.